SCHEMBL14320696

SCHEMBL14320696

COc1ccc(Cn2cc3nc(-c4ccccc4F)nc(Cl)c3n2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.44
LMNA P02545 1/20 0.44
KCNH2 Q12809 1/20 0.42
TP53 P04637 5/20 0.42
ADORA3 P0DMS8 5/20 0.41
ADORA2A P29274 4/20 0.41
ADORA1 P30542 4/20 0.41
ADORA2B P29275 2/20 0.41
DHPS P49366 1/20 0.40
EPHB4 P54760 1/20 0.40
SMN1; SMN2 Q16637 4/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39
TUBA1B P68363 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14320490 0.90 ADORA3 (0.43) MAPTLMNATP53ADORA3ADORA2A
SCHEMBL14320330 0.88 ADORA3 (0.44) MAPTTP53ADORA3ADORA2AADORA1
SCHEMBL14320942 0.88 ADORA3 (0.40) MAPTTP53ADORA3ADORA2AADORA1
SCHEMBL13734251 0.87 MEN1 (0.44) MAPTLMNATP53ADORA3ADORA2A
SCHEMBL15651059 0.87 ADORA3 (0.46) TP53ADORA3ADORA2AADORA1ADORA2B
SCHEMBL15651499 0.85 TP53 (0.44) MAPTTP53ADORA3ADORA2AADORA1
SCHEMBL15651570 0.85 ADORA3 (0.46) TP53ADORA3ADORA2AADORA1ADORA2B
SCHEMBL13734641 0.84 ADORA3 (0.58) TP53ADORA3ADORA2AADORA1ADORA2B
SCHEMBL15649956 0.84 TP53 (0.41) MAPTLMNATP53ADORA3ADORA2A
SCHEMBL15651505 0.84 ADORA3 (0.45) TP53ADORA3ADORA2AADORA1ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP claimed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US claimed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 US disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP disclosed
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-24 US disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS LRRK2, MYLK2, MYLK MAPT 501/4885LMNA 3243/4885KCNH2 1736/4885
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK MAPT 470/4885LMNA 3015/4885KCNH2 1965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.